Atossa Therapeutics, Inc.’s Post

Early #diagnostic of #pancreaticcancer : 2 important announces this week from Immunovia AB and City of Hope Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study https://lnkd.in/gm_ncUNy An Exosome-based Liquid Biopsy Shows Promise for Early Detection of Pancreatic Cancer https://lnkd.in/dj5CZUB6 However, predictive diagnostics developed by ACOBIOM are needed to target 1st line therapies (#gemcitabine, #FOLFIRINOX). For more information: https://lnkd.in/gFGE6-AW

Roche Gains CE Mark for VENTANA FOLR1 Assay Roche’s VENTANA FOLR1 (FOLR1-2.1) RxDx Assay has secured CE Mark approval, becoming the first immunohistochemistry companion diagnostic in Europe for epithelial ovarian cancer (EOC). The test identifies FRɑ-positive, platinum-resistant ovarian cancer patients eligible for AbbVie’s ELAHERE (mirvetuximab soravtansine), addressing a critical need for targeted treatment options. Read more: https://lnkd.in/d-pxR-7n #Roche #CEApproval #OvarianCancer #FRAPositive #ELAHERE #PrecisionMedicine #OncologyDiagnostics

#ASCO24: GenFleet highlights Phase 2 data on KRAS/EGFR combo in lung cancer https://lnkd.in/gCx3byzU As companies increasingly look to combinations to boost the efficacy of KRAS therapies, a Phase 2 study is offering some of the first clinical evidence for combining KRAS and EGFR in frontline lung cancer. On [...]

For National Cancer Research Month, we want to say thank you to our team and the researchers, clinicians, and patients who are taking part in clinical trials to advance new therapeutics. We've made important progress, but there is still much to be done. Together, we can push forward and make a difference in the lives of those affected by #cancer. Learn more about our #clinicaltrials and the contributions Janux is making to #cancerresearch: https://lnkd.in/ggvVSxn3 #NCRM24 #CancerResearchSavesLives #TCellEngagers #cancer #oncology #immunotherapy #immunomodulators

Our lead program #ENV105 is an antibody that inhibits CD105 to reverse #drug resistance and restore the effectiveness of standard cancer therapies. ENV105 focuses on eliminating resistance mechanisms within #cancer cells, setting it apart from therapies that introduce new drugs when tumors become resistant. In our published Phase 2 clinical trial with ENV105 and prostate cancer patients, we received a 62% clinical response rate. Our ongoing expanded Phase 2 prostate cancer trial using ENV105 with apalutamide (Janssen) has received support from the NCI/NIH by a grant. Learn more here - https://loom.ly/ICzn8gw NYSE: KAPA

#NEWS: We have acquired Nerio Therapeutics. Why? Their knowledge will help us to fight cancer by activating our own immune system. Learn more on why we have added their small molecule checkpoint inhibitor to our oncology pipeline: https://lnkd.in/e9i3SdqY #Cancer #ImmunoOncology #ResearchAndDevelopment

We’re thrilled to announce that #preclinicaldata highlighting the differentiating properties of MYTX-011, our investigational cMET-targeting #ADC, has been published in the latest issue of Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research. Learn more: https://lnkd.in/ezrt85xm.   Discover how MYTX-011 has the potential to benefit a broader set of patients by offering increased on-target potency, enhanced tolerability, a longer half-life and higher efficacy when compared to other ADCs. Read the full article here: https://lnkd.in/eM44ZFH4.  

I am delighted to announce the publication of our latest research article, "Preparation of UiO-66 loaded Letrozole nano-drug delivery system: enhanced anticancer and apoptosis activity," in AMB Express (IF = 3.7). In this study, we developed a novel nano-drug delivery system using UiO-66 nanoparticles to enhance the efficacy of Letrozole, a drug commonly used for breast cancer treatment. Our findings show significant improvements in targeting and treating breast cancer cells, offering new insights into cancer therapeutics. Read the full article for a deeper understanding of our innovative approach: https://lnkd.in/gxHWWCfQ Springer Nature Group #AMBExpress  #BreastCancer #CancerResearch

Highly recommended this webinar relevant for any one involved in the treatment of patients with lung cancer. Learn everything about drug-drug interactions, the pros and cons of TDM, and management of toxicity, including discussion of ESMO - European Society for Medical Oncology guidelines. You are all welcome!!

🔬 Insights from ASCO 2024! Prof els Van Nieuwenhuysen from University Hospitals Leuven presents the ongoing trial on ubamatamab for recurrent ovarian and endometrial cancer. The study explores dose escalation, early efficacy signals, and strategies to mitigate cytokine release syndrome. Learn more about the potential of this bispecific antibody therapy. Discover these updates.👇 For all ASCO 2024 videos, find the link in the comments! #MediMix #ASCO2024 #GynaecologicalCancer #OncologyInnovation #OvarianCancer #EndometrialCancer